Page 110 - Livre électronique des RFTP 2024

DRUG-INDUCED EOSINOPHILIA, STUDY BASED ON

THE TUNISIAN NATIONAL CENTER OF PHARMACO-
VIGILANCE DATABASE.

Y.MAHJOUBI, S. DEBBECHE, I. HAMZA, W. KAABI, A. ZAIEM, G. LAKHOUA, S. KASTALLI,
S. EL AIDLI

SERVICE DE RECUEIL ET D'ANALYSE DES EFFETS INDESIRABLES, CENTRE NATIONAL DE
PHARMACOVIGILANCE

INTRODUCTION:

Eosinophilia is when the peripheral blood eosinophil count is greater than 500 cells
per mm3. Drug induced eosinophilia (DIE) is a rare adverse effect that is commonly
reported with penicillins or sulfonamides.

AIM:

To describe the clinical characteristics, the causative drugs and the outcome of
cases of DIE notified to the National Center of Pharmacovigilance, Tunisia.

METHODS:

We carried a retrospective study including cases of eosinophila notified to the
National centre of Pharmacovigilance, Tunisia from April 2021 to March 2024. Cases
were included if eosinophilia was not associated to cutaneous or systemic
symptoms.

All cases were analyzed according to the French Imputability method of causality
assessment.

RESULTS:

There were 12 patients (9 men and 3 women). The median age was 53.5 years
(range: 15-80). Notifications were from psychiatrists (n=4), neurologists and
internists in 3 cases each. The remaining two cases were notified by an oncologist
and an otorhinolaryngologist.

Personal atopy was found in two cases: allergic rhinitis and asthma.
Causative drugs were clozapine (n=4) and captopril (n=3). Other causative
medications included amitriptyline, piroxicam, ciprofloxacin, natalizumab, and
atezolizumab, each in one case.

Eosinophilia occurred within a median of 5.5 months after drug initiation, with
variations ranging from 21days to 15years.

Eosinophilia was mild (500 to 1500/mm³) in nine cases and moderate (1500 to
5000/mm³) in three cases. There were no severe cases (higher than 5000/mm³)

Eosinophilia ranged from 813 to 4960/mm³, with a median level of 1203/mm³.

108 | P age